Sandoz Group AG

Sandoz Group AG is a leading global pharmaceutical company specializing in the development, manufacture, and commercialization of generic pharmaceuticals and biosimilars. Founded in 1886 and headquartered in Basel, Switzerland, it emerged as an independent entity following its spin-off from Novartis in October 2023. The company’s core divisions encompass retail generics—which include finished dosage forms of small-molecule drugs—biopharmaceuticals, and anti-infectives, providing an extensive portfolio of more than 1,500 products to patients in over 100 countries. Its biosimilar portfolio covers key therapeutic areas such as oncology, diabetes, immunology, and endocrinology, while the generics business focuses on a wide range of medical needs including cardiovascular, central nervous system, and anti-infective treatments. Sandoz serves global healthcare providers by increasing access to affordable, high-quality medicines, making it a critical player in the healthcare and pharmaceutical sectors. Its significant clinical visibility and robust pipeline of biosimilars underscore its influential role in driving competition and innovation across drug markets.